Not available
Quote | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
Last: | $33.77 |
---|---|
Change Percent: | 0.0% |
Open: | $33.04 |
Close: | $33.77 |
High: | $33.84 |
Low: | $31.995 |
Volume: | 527,839 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
2024-03-20 17:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-07 18:32:11 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Conference Call March 07, 2024 04:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President &a...
Message Board Posts | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $ARCT 30% v4,9M c20.17 f26,5M H20.74 ML14.21 gap N Hold18 | znewcar1 | investorshangout | 03/30/2023 3:18:11 AM |
whytestocks: $ARCT News Article - Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? | whytestocks | investorshangout | 11/02/2022 3:15:49 PM |
znewcar1: ARCT 25% v1M c20.88 f26,4M H20.89 | znewcar1 | investorshangout | 05/27/2022 8:26:13 PM |
Silence is golden ARC | IOUBLOKE1 | investorshub | 12/20/2021 3:43:30 PM |
Wow big after hours green buy | IOUBLOKE1 | investorshub | 12/17/2021 10:01:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
2024-03-20 17:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated ...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...